EQUITY RESEARCH / 2026 → 2029
Find a business worth researching. Understand what could drive growth, what could break the thesis, and how much success the entry price already assumes.
Research priorities reviewed 2026-09-23 · Editorial judgement, not a buy signal · Capital can be lost
SECTOR RESEARCH
Curated themes, not an industry index. Compare the business drivers first, then inspect individual companies and their entry valuations.
Compute, memory and optical links can benefit from larger AI deployments.
CRDO NBIS ALAB MU AMD AMAT ANET AVGO COHR AAOI
What to track: Organic revenue; customer concentration; cash after capex; product margins.
Risk: AI spending is shared exposure: several tickers can depend on the same customers.
Electricity delivery and heat removal may constrain data-center expansion.
VRT ETN GEV
What to track: Organic orders; backlog conversion; factory capacity; cash conversion.
Risk: Grid delays, capex cycles and high entry valuations.
Generation, components and fuel offer different exposure to nuclear investment.
BWXT CEG LEU
What to track: Funded contracts; outages; fuel capacity; maintenance and expansion capex.
Risk: Permits, policy, project timing and financing; generators and fuel developers are not interchangeable.
Launch, communication and imaging require different paths to commercial scale.
RKLB ASTS PL RDW
What to track: Operational launches; paid usage; backlog conversion; funded cash runway.
Risk: Launch failures, customer concentration and dilution.
Unmanned platforms and counter-drone systems may attract procurement.
AVAV KTOS
What to track: Funded backlog; production deliveries; organic margins; cash collections.
Risk: Budget changes, program selection and contract execution losses.
Robotics, connected operations and testing can improve physical productivity.
SYM IOT TER
What to track: Installation economics; recurring usage; customer concentration; segment margins.
Risk: Slow deployments and cyclical industrial or semiconductor budgets.
Diagnostics, surgical tools and drug discovery have distinct clinical and payment risks.
TEM HIMS RXRX ISRG NTRA GH TMDX
What to track: Reimbursed volumes; clinical milestones; collections; cash runway.
Risk: Trial failure, reimbursement and regulation; do not value a drug pipeline like software.
Recurring tools support cloud operations, security and development.
NET CRWD DDOG
What to track: Retention; consumption; recurring revenue; GAAP margins; diluted shares.
Risk: Competition, service incidents, stock compensation and entry multiples.
Advertising, cloud services and learning subscriptions can scale with engagement.
GOOGL DUOL APP
What to track: Paid retention; advertiser returns; cash flow; organic growth.
Risk: Platform dependence, AI substitution, privacy rules and acquisition costs.
Useful technical performance must turn into repeat paid commercial demand.
IONQ QBTS RGTI QUBT
What to track: External orders; organic revenue; cash burn; reproducible technical milestones.
Risk: Technical uncertainty, lumpy sales, acquisitions and dilution.
Higher energy density matters only if manufacturing becomes commercially viable.
ENVX
What to track: Qualified customers; manufacturing yield; unit cost; funded capacity.
Risk: Qualification delays, yield failures and financing.
A broader customer relationship can support fee revenue and operating scale.
SOFI
What to track: Credit losses; capital adequacy; deposit costs; normalized earnings.
Risk: Credit cycles and regulation; software sales multiples are inappropriate.
Coverage counts refer to this entire list and its current snapshots. Positive margin counts use only issuers with a known trailing-four-quarter net margin; a dash means unavailable. Different fiscal periods and business models are not directly comparable.
| Company | Research priority | Risk | Why research it? | Dated observations |
|---|---|---|---|---|
| CRDOCredo TechnologyAI connectivityCommercial growth | Research priority★★★★☆4 / 5 | RiskHigh4 / 5 | Higher bandwidth creates demand for efficient links inside AI clusters. Thesis, risks & sourcesWhat must go rightBroader customer adoption and sustained margins as connectivity speeds rise. What would break the thesisCustomer concentration, competing optical designs or margin compression. Before assessing cheapnessCompare forward earnings and free cash flow with customer concentration. Exceptional-return scenario10× needs sustained expansion well beyond the current customer base; valuation is unverified. Company newsroom lists FY2027 Q1 results and optical connectivity updates. Company source ↗ Company facts → |
$150.99Stored close · 2026-10-30-50.1%From 252-session closing peak
63-session change -30.8%252-session change -12.0%
Revenue growth 114.7%Net margin 33.8%ROE 19.7%EPS acceleration —Reporting period 2026-08-01SEC · 2026-09-02 ↗
|
| NBISNebiusAI cloudCommercial growth | Research priority★★★★☆4 / 5 | RiskExtreme5 / 5 | AI compute demand may support a larger specialist cloud business. Thesis, risks & sourcesWhat must go rightCommission capacity, fill it with paying customers and improve cash returns. What would break the thesisPower delays, underutilized GPUs, capex funding and shareholder dilution. Before assessing cheapnessValue cash flow after capex and debt; contracted demand is not earned revenue. Exceptional-return scenario10× is an exceptional execution and funding scenario, not a base case. Q2 2026 results published August 12; AI cloud business and investment exposure disclosed. Company source ↗ SEC metrics not covered |
—Recent close unavailable SEC metrics not covered |
| RKLBRocket LabSpace systems & launchCommercial growth | Research priority★★★★☆4 / 5 | RiskExtreme5 / 5 | Launch services and spacecraft systems can serve growing commercial and defense demand. Thesis, risks & sourcesWhat must go rightConvert contracted backlog to cash and deliver the Neutron program. What would break the thesisLaunch failures, development delays, acquisition integration and dilution. Before assessing cheapnessSeparate organic sales, acquisition effects, capex and fully diluted shares. Exceptional-return scenario10× requires much more than a successful launch; funding and entry valuation matter. Q2 2026 release reports growing revenue/backlog and an announced Iridium acquisition. Company source ↗ Company facts → |
$54.73Stored close · 2026-10-30-63.6%From 252-session closing peak
63-session change -22.3%252-session change -17.3%
Revenue growth 62.0%Net margin -21.5%ROE -4.7%EPS acceleration —Reporting period 2026-06-30SEC · 2026-08-10 ↗
|
| ALABAstera LabsAI connectivityCommercial growth | Research priority★★★★☆4 / 5 | RiskHigh4 / 5 | More complex AI systems need additional connectivity and switching products. Thesis, risks & sourcesWhat must go rightScale Scorpio deployments and diversify product and customer revenue. What would break the thesisCustomer concentration, competitive standards and a high entry valuation. Before assessing cheapnessCheck revenue multiple, cash generation and stock-based compensation. Exceptional-return scenario10× needs product expansion plus a defensible entry multiple; growth alone is insufficient. Q2 2026 release discusses Scorpio deployment and expansion of connectivity products. Company source ↗ Company facts → |
$258.70Stored close · 2026-10-30-46.4%From 252-session closing peak
63-session change -19.4%252-session change +49.0%
Revenue growth 104.5%Net margin 30.7%ROE 21.4%EPS acceleration 41.8 ppReporting period 2026-06-30SEC · 2026-08-05 ↗
|
| VRTVertivPower & coolingCommercial growth | Research priority★★★★☆4 / 5 | RiskHigh4 / 5 | AI capacity needs power management and heat removal as well as chips. Thesis, risks & sourcesWhat must go rightDeliver liquid cooling and power capacity with healthy cash conversion. What would break the thesisHyperscaler capex slowdown, manufacturing bottlenecks and pricing pressure. Before assessing cheapnessCheck organic growth, working capital and free cash flow after capacity investment. Exceptional-return scenario10× would require exceptional expansion from an already established business; entry valuation is unverified. July 29, 2026 release: Q2 sales rose 24%, including 18% organic growth. Company source ↗ Company facts → |
$232.50Stored close · 2026-10-30-38.2%From 252-session closing peak
63-session change -11.6%252-session change +16.7%
Revenue growth 61.2%Net margin 16.0%ROE 38.1%EPS acceleration 38.2 ppReporting period 2026-09-30SEC · 2026-10-28 ↗
|
| ETNEatonElectrical equipmentComparison businesses | Research priority★★★★☆4 / 5 | RiskSubstantial3 / 5 | Grid expansion and data centers require electrical distribution and protection equipment. Thesis, risks & sourcesWhat must go rightConvert electrical backlog into deliveries while preserving margins. What would break the thesisProject delays, acquisition integration and a premium entry valuation. Before assessing cheapnessSeparate organic sales from acquisitions; compare cash earnings with normalized capex. Exceptional-return scenarioEstablished industry comparison; 10× over 2–3 years is not a base case. Q2 2026 release: sales rose 21%, comprising 14% organic growth and 7% from acquisitions. Company source ↗ Company facts → |
$366.07Stored close · 2026-11-02-20.4%From 252-session closing peak
63-session change -17.7%252-session change -4.4%
Revenue growth 21.4%Net margin 12.8%ROE 18.9%EPS acceleration -6.5 ppReporting period 2026-06-30SEC · 2026-07-31 ↗
|
| GEVGE VernovaGrid & generation equipmentComparison businesses | Research priority★★★★☆4 / 5 | RiskHigh4 / 5 | Grid equipment, power generation and services address growing electricity requirements. Thesis, risks & sourcesWhat must go rightConvert Power and Electrification orders into profitable deliveries. What would break the thesisLong delivery cycles, wind losses, warranty costs and execution risk. Before assessing cheapnessSeparate equipment and service economics; orders and customer advances are not earnings. Exceptional-return scenarioIndustry comparison; a large backlog does not establish a 10× share-price opportunity. July 22, 2026 release: Q2 revenue rose 22%, or 12% organically, led by Power and Electrification. Company source ↗ Company facts → |
$857.87Stored close · 2026-10-30-27.0%From 252-session closing peak
63-session change -14.8%252-session change +48.4%
Revenue growth 26.8%Net margin 23.5%ROE 91.1%EPS acceleration 160.5 ppReporting period 2026-09-30SEC · 2026-10-28 ↗
|
| BWXTBWX TechnologiesNuclear componentsCommercial growth | Research priority★★★★☆4 / 5 | RiskHigh4 / 5 | Nuclear components and services participate in defense and commercial reactor investment. Thesis, risks & sourcesWhat must go rightDeliver funded programs and expand manufacturing with disciplined cash returns. What would break the thesisGovernment concentration, project overruns and acquisition integration. Before assessing cheapnessInspect funded backlog, contract margins and free cash flow after factory expansion. Exceptional-return scenario10× needs exceptional per-share growth; nuclear exposure alone does not support it. August 3, 2026 release reports Q2 revenue of $901.6m and net income of $89.1m. Company source ↗ Company facts → |
$130.70Stored close · 2026-10-30-45.2%From 252-session closing peak
63-session change -24.8%252-session change -38.8%
Revenue growth 18.0%Net margin 10.1%ROE 26.6%EPS acceleration -6.6 ppReporting period 2026-06-30SEC · 2026-08-05 ↗
|
| ANETArista NetworksData-center networkingComparison businesses | Research priority★★★★☆4 / 5 | RiskHigh4 / 5 | Larger AI clusters require high-bandwidth Ethernet networking and software. Thesis, risks & sourcesWhat must go rightConvert AI networking deployments into sustained sales and customer diversification. What would break the thesisHyperscaler concentration, competing architectures and valuation compression. Before assessing cheapnessCheck customer acceptance terms, inventory and cash conversion alongside earnings. Exceptional-return scenarioEstablished networking comparison; no supported 10× forecast from demand growth alone. Investor materials link Q2 2026 results and cloud/AI networking presentations. Company source ↗ Company facts → |
$168.86Stored close · 2026-10-30-22.1%From 252-session closing peak
63-session change -8.7%252-session change +4.2%
Revenue growth 37.7%Net margin 38.4%ROE 27.3%EPS acceleration 10.7 ppReporting period 2026-06-30SEC · 2026-08-05 ↗
|
| ASTSAST SpaceMobileSatellite connectivityFrontier technology | Research priority★★★☆☆3 / 5 | RiskExtreme5 / 5 | Direct-to-phone satellite broadband could open a new connectivity market. Thesis, risks & sourcesWhat must go rightLaunch and commission satellites, obtain approvals and convert coverage into paid service. What would break the thesisLaunch or deployment failure, spectrum limits, funding needs and dilution. Before assessing cheapnessModel funded satellite deployment and paying usage, not only addressable market. Exceptional-return scenario10× depends on network economics and funding; technical success alone is insufficient. Investor page describes the direct-to-cell network and links Q2 2026 filings. Company source ↗ Company facts → |
$40.97Stored close · 2026-10-30-69.2%From 252-session closing peak
63-session change -35.5%252-session change -48.8%
Revenue growth —Net margin —ROE -25.8%EPS acceleration —Reporting period 2026-06-30SEC · 2026-08-10 ↗
|
| PLPlanet LabsEarth observationCommercial growth | Research priority★★★☆☆3 / 5 | RiskHigh4 / 5 | Repeated Earth imagery can support government and commercial data subscriptions. Thesis, risks & sourcesWhat must go rightRenew contracts, expand analytics usage and convert bookings into cash. What would break the thesisGovernment budget concentration, competition and satellite replacement costs. Before assessing cheapnessCheck recurring revenue quality, gross margin and cash flow after constellation costs. Exceptional-return scenario10× needs durable cash-generating scale; no probability is assigned. Company investor overview; current valuation has not been validated. Company source ↗ Company facts → |
$13.47Stored close · 2026-10-30-73.8%From 252-session closing peak
63-session change -37.4%252-session change +4.4%
Revenue growth 58.1%Net margin -95.1%ROE -63.8%EPS acceleration —Reporting period 2026-07-31SEC · 2026-09-03 ↗
|
| RDWRedwireSpace & defenseCommercial growth | Research priority★★★☆☆3 / 5 | RiskExtreme5 / 5 | Space infrastructure and defense platforms can benefit from program expansion. Thesis, risks & sourcesWhat must go rightExecute contracts, integrate acquired operations and convert backlog into cash. What would break the thesisProgram delays, acquisition integration, debt and contract execution losses. Before assessing cheapnessCheck organic growth, debt, working capital and cash conversion. Exceptional-return scenario10× requires profitable expansion without excessive dilution or leverage. Investor page describes space/defense operations and links Q2 2026 results. Company source ↗ Company facts → |
$8.39Stored close · 2026-10-30-67.6%From 252-session closing peak
63-session change -13.0%252-session change +6.9%
Revenue growth 89.6%Net margin -57.3%ROE -15.0%EPS acceleration —Reporting period 2026-06-30SEC · 2026-08-06 ↗
|
| TEMTempus AIHealthcare dataCommercial growth | Research priority★★★☆☆3 / 5 | RiskHigh4 / 5 | Diagnostics and clinical data may support a growing precision-medicine business. Thesis, risks & sourcesWhat must go rightGrow paid testing and data licensing with improving unit economics. What would break the thesisReimbursement, privacy obligations, competition and integration costs. Before assessing cheapnessSeparate diagnostics margins from data licensing and exclude acquisition-only growth. Exceptional-return scenario10× requires durable per-share economics; the AI label is not a valuation model. Investor overview describes diagnostics and clinical-data products. Company source ↗ Company facts → |
$72.22Stored close · 2026-10-30-19.6%From 252-session closing peak
63-session change +56.8%252-session change -18.7%
Revenue growth 21.6%Net margin -17.8%ROE -57.2%EPS acceleration —Reporting period 2026-06-30SEC · 2026-07-30 ↗
|
| HIMSHims & HersDigital healthCommercial growth | Research priority★★★☆☆3 / 5 | RiskExtreme5 / 5 | Digital distribution can broaden access to repeat-purchase healthcare services. Thesis, risks & sourcesWhat must go rightImprove retention and expand compliant product offerings with profitable acquisition costs. What would break the thesisProduct regulation, supplier access, customer acquisition costs and churn. Before assessing cheapnessCheck sustainable gross profit, retention and cash flow by product line. Exceptional-return scenario10× would require durable expansion; a temporary product surge is insufficient. Company investor overview; SEC metrics are shown separately when covered. Company source ↗ Company facts → |
$27.68Stored close · 2026-10-30-39.1%From 252-session closing peak
63-session change -10.2%252-session change -40.6%
Revenue growth 38.2%Net margin -5.5%ROE -43.8%EPS acceleration -17.6 ppReporting period 2026-06-30SEC · 2026-08-10 ↗
|
| IONQIonQQuantum computingFrontier technology | Research priority★★★☆☆3 / 5 | RiskExtreme5 / 5 | Useful quantum systems could create demand for computing and related infrastructure. Thesis, risks & sourcesWhat must go rightDemonstrate paid deployments, repeat orders and useful technical performance. What would break the thesisCommercial utility may arrive late; cash burn, acquisitions and valuation can dominate. Before assessing cheapnessSeparate organic revenue from acquired businesses; inspect cash burn and diluted shares. Exceptional-return scenario10× is a tail scenario dependent on commercial adoption and entry valuation. Q2 2026 release discloses commercial deployments, losses and the SkyWater acquisition. Company source ↗ Company facts → |
$30.04Stored close · 2026-10-30-58.3%From 252-session closing peak
63-session change -22.7%252-session change -50.8%
Revenue growth 286.8%Net margin -553.3%ROE -41.0%EPS acceleration —Reporting period 2026-06-30SEC · 2026-08-10 ↗
|
| SOFISoFi TechnologiesFinancial servicesComparison businesses | Research priority★★★☆☆3 / 5 | RiskHigh4 / 5 | Broader financial services may increase customer revenue and operating scale. Thesis, risks & sourcesWhat must go rightGrow durable fee income while controlling credit losses and acquisition costs. What would break the thesisCredit deterioration, funding costs, regulation and valuation compression. Before assessing cheapnessCheck normalized earnings, credit losses, capital and tangible book value. Exceptional-return scenarioIncluded as a comparison business; 10×/100× is not an underwriting assumption. Company investor overview; current valuation is unverified in this screen. Company source ↗ Company facts → |
$16.76Stored close · 2026-10-30-48.0%From 252-session closing peak
63-session change -7.0%252-session change -45.8%
Revenue growth 1.1%Net margin 104.3%ROE 5.7%EPS acceleration -50.0 ppReporting period 2026-06-30SEC · 2026-08-06 ↗
|
| MUMicronMemory semiconductorsComparison businesses | Research priority★★★☆☆3 / 5 | RiskHigh4 / 5 | AI systems require additional memory capacity and bandwidth. Thesis, risks & sourcesWhat must go rightHBM execution and sustained returns on capacity investment through the cycle. What would break the thesisMemory oversupply, cyclical pricing, capex and export restrictions. Before assessing cheapnessUse mid-cycle earnings and cash flow; peak-cycle P/E can look misleadingly cheap. Exceptional-return scenarioCycle comparison, not a validated 10× or 100× candidate. Investor materials discuss AI memory demand, HBM and capacity investment. Company source ↗ Company facts → |
$833.59Stored close · 2026-11-02-31.3%From 252-session closing peak
63-session change -6.6%252-session change +272.1%
Revenue growth 379.3%Net margin 63.8%ROE 61.4%EPS acceleration 612.4 ppReporting period 2026-09-03SEC · 2026-10-09 ↗
|
| AMDAdvanced Micro DevicesCompute semiconductorsComparison businesses | Research priority★★★☆☆3 / 5 | RiskHigh4 / 5 | Server processors and accelerators can participate in AI infrastructure spending. Thesis, risks & sourcesWhat must go rightAccelerator adoption, software execution and profitable server share growth. What would break the thesisStrong competition, customer concentration, supply constraints and export rules. Before assessing cheapnessCompare earnings and free cash flow with accelerator margins and dilution. Exceptional-return scenarioComparison company; being smaller than a competitor does not establish 10× upside. Investor materials include Q2 2026 results and AI infrastructure partnerships. Company source ↗ Company facts → |
$466.84Stored close · 2026-11-02-28.1%From 252-session closing peak
63-session change -10.0%252-session change +83.2%
Revenue growth 50.1%Net margin 15.6%ROE 9.6%EPS acceleration 64.6 ppReporting period 2026-06-27SEC · 2026-08-05 ↗
|
| AMATApplied MaterialsChipmaking equipmentComparison businesses | Research priority★★★☆☆3 / 5 | RiskSubstantial3 / 5 | More complex chips can increase demand for process equipment and services. Thesis, risks & sourcesWhat must go rightTechnology transitions and sustained customer investment. What would break the thesisSemiconductor capex cycles, export restrictions and customer concentration. Before assessing cheapnessCompare mid-cycle cash earnings and services durability with the entry price. Exceptional-return scenarioEquipment-cycle comparison; 10×/100× is not an investment premise. Company investor relations; no claim that the current price is cheap. Company source ↗ Company facts → |
$374.53Stored close · 2026-11-02-48.2%From 252-session closing peak
63-session change -31.5%252-session change +61.1%
Revenue growth 24.8%Net margin 30.1%ROE 36.2%EPS acceleration 9.3 ppReporting period 2026-07-26SEC · 2026-08-20 ↗
|
| GOOGLAlphabetCloud & digital platformsComparison businesses | Research priority★★★☆☆3 / 5 | RiskSubstantial3 / 5 | Cloud growth and AI products may add to an established digital business. Thesis, risks & sourcesWhat must go rightMonetize AI while sustaining search economics and returns on capex. What would break the thesisSearch disruption, antitrust remedies and heavy infrastructure spending. Before assessing cheapnessCheck free cash flow after AI capex and the durability of search margins. Exceptional-return scenarioEstablished-business comparison; no supported 10×/100× thesis over 2–3 years. Alphabet investor materials; cheapness requires a verified entry valuation. Company source ↗ SEC metrics not covered |
—Recent close unavailable SEC metrics not covered |
| CEGConstellation EnergyPower generationComparison businesses | Research priority★★★☆☆3 / 5 | RiskHigh4 / 5 | Existing nuclear generation can supply reliable electricity to growing loads. Thesis, risks & sourcesWhat must go rightSign attractive power contracts and operate the generation fleet reliably. What would break the thesisOutages, power-price changes, integration costs and regulatory intervention. Before assessing cheapnessModel contracted versus merchant power prices, maintenance capex and debt. Exceptional-return scenarioEstablished generator comparison; growth in electricity demand is not a 10× forecast. Investor materials describe a diversified generation fleet, nuclear operations and the Calpine transaction. Company source ↗ Company facts → |
$262.38Stored close · 2026-10-30-31.4%From 252-session closing peak
63-session change -4.1%252-session change -34.6%
Revenue growth 13.2%Net margin 14.0%ROE 10.8%EPS acceleration -1128.4 ppReporting period 2026-06-30SEC · 2026-08-06 ↗
|
| AVGOBroadcomCustom compute & networkingComparison businesses | Research priority★★★☆☆3 / 5 | RiskHigh4 / 5 | Custom accelerators and networking may capture a share of AI infrastructure spending. Thesis, risks & sourcesWhat must go rightScale custom compute programs and maintain recurring infrastructure software economics. What would break the thesisCustomer concentration, leverage, program delays and multiple compression. Before assessing cheapnessSeparate semiconductor cyclicality from software cash flow; include debt and dilution. Exceptional-return scenarioLarge established-business comparison, not a validated 10× or 100× candidate. Company investor materials cover semiconductor solutions and infrastructure software. Company source ↗ Company facts → |
$322.23Stored close · 2026-11-02-33.1%From 252-session closing peak
63-session change -22.9%252-session change -14.4%
Revenue growth 85.5%Net margin —ROE —EPS acceleration 129.9 ppReporting period 2026-08-02SEC · 2026-09-10 ↗
|
| COHRCoherentOptical componentsCommercial growth | Research priority★★★☆☆3 / 5 | RiskHigh4 / 5 | Faster data-center links increase the need for optical transceivers and photonics. Thesis, risks & sourcesWhat must go rightExpand high-speed optical capacity with sustained yields and margins. What would break the thesisOptical pricing pressure, customer concentration, debt and manufacturing execution. Before assessing cheapnessCheck organic sales, leverage and cash flow after capacity spending. Exceptional-return scenario10× needs durable per-share cash growth and a defensible entry valuation. August 12, 2026 release: fiscal Q4 revenue of $2.05bn, up 34% year on year. Company source ↗ Company facts → |
$210.32Stored close · 2026-10-30-50.7%From 252-session closing peak
63-session change -27.0%252-session change +52.3%
Revenue growth 33.7%Net margin 11.3%ROE 7.4%EPS acceleration —Reporting period 2026-06-30SEC · 2026-08-14 ↗
|
| AAOIApplied OptoelectronicsOptical transceiversCommercial growth | Research priority★★★☆☆3 / 5 | RiskExtreme5 / 5 | Optical links can benefit from increasing data-center bandwidth requirements. Thesis, risks & sourcesWhat must go rightWin repeat high-speed transceiver orders and improve production yields. What would break the thesisCustomer concentration, product qualification delays, losses and funding needs. Before assessing cheapnessCheck sustainable gross profit, capex and cash runway instead of extrapolating a small base. Exceptional-return scenarioA speculative manufacturing scale-up; volume growth may not translate into per-share value. Company investor materials describe fiber-optic access and data-center products. Company source ↗ Company facts → |
$69.05Stored close · 2026-10-30-69.0%From 252-session closing peak
63-session change -37.3%252-session change +94.6%
Revenue growth 86.4%Net margin -9.6%ROE -3.4%EPS acceleration —Reporting period 2026-06-30SEC · 2026-08-06 ↗
|
| SYMSymboticWarehouse automationCommercial growth | Research priority★★★☆☆3 / 5 | RiskExtreme5 / 5 | Warehouse automation can reduce handling costs and increase throughput. Thesis, risks & sourcesWhat must go rightInstall systems on time and grow profitable recurring service revenue. What would break the thesisCustomer concentration, installation delays and cost overruns. Before assessing cheapnessCheck backlog cancellation terms, deployment margins and cash advances. Exceptional-return scenario10× requires successful deployment at scale and attractive economics for shareholders. Company investor materials describe robotic warehouse systems and software. Company source ↗ Company facts → |
$37.93Stored close · 2026-10-30-56.6%From 252-session closing peak
63-session change -17.3%252-session change -51.2%
Revenue growth 21.7%Net margin 0.5%ROE 1.8%EPS acceleration —Reporting period 2026-06-27SEC · 2026-08-05 ↗
|
| IOTSamsaraConnected operationsCommercial growth | Research priority★★★☆☆3 / 5 | RiskHigh4 / 5 | Fleet and industrial data can support recurring software for physical operations. Thesis, risks & sourcesWhat must go rightExpand paid deployments while sustaining retention and sales efficiency. What would break the thesisCompetition, hardware costs, customer budgets and share-based compensation. Before assessing cheapnessCompare recurring revenue growth, retention and free cash flow after dilution. Exceptional-return scenario10× is exceptional; recurring revenue alone does not justify any entry multiple. Company investor overview describes its Connected Operations platform. Company source ↗ Company facts → |
$42.07Stored close · 2026-10-30-7.0%From 252-session closing peak
63-session change +13.3%252-session change +7.0%
Revenue growth 29.9%Net margin 4.9%ROE 5.7%EPS acceleration —Reporting period 2026-08-01SEC · 2026-09-08 ↗
|
| TERTeradyneTest equipment & roboticsComparison businesses | Research priority★★★☆☆3 / 5 | RiskHigh4 / 5 | More complex chips need testing, while industrial automation offers another demand channel. Thesis, risks & sourcesWhat must go rightConvert semiconductor test demand and improve robotics economics. What would break the thesisSemiconductor cycles, customer concentration and uneven robot adoption. Before assessing cheapnessUse segment-level and mid-cycle earnings; do not treat test revenue as robotics revenue. Exceptional-return scenarioIndustrial comparison; no supported 10×/100× premise. Company investor materials cover semiconductor test and robotics businesses. Company source ↗ Company facts → |
$274.37Stored close · 2026-10-30-43.3%From 252-session closing peak
63-session change -25.0%252-session change +57.7%
Revenue growth 103.9%Net margin 25.8%ROE 33.5%EPS acceleration 71.0 ppReporting period 2026-06-28SEC · 2026-07-31 ↗
|
| AVAVAeroVironmentAutonomous defense systemsCommercial growth | Research priority★★★☆☆3 / 5 | RiskHigh4 / 5 | Demand for unmanned systems and counter-drone capabilities may support defense programs. Thesis, risks & sourcesWhat must go rightScale funded production and convert contracts into cash. What would break the thesisProcurement delays, contract losses, integration risk and export restrictions. Before assessing cheapnessSeparate organic growth from acquired operations and inspect funded backlog. Exceptional-return scenario10× needs exceptional program expansion and cash generation; awards are not revenue. Investor page links fiscal Q1 2027 results dated September 9, 2026 and describes autonomous and counter-UAS systems. Company source ↗ Company facts → |
$126.11Stored close · 2026-10-30-67.9%From 252-session closing peak
63-session change -20.8%252-session change -66.9%
|
| KTOSKratos DefenseDefense platforms & propulsionCommercial growth | Research priority★★★☆☆3 / 5 | RiskExtreme5 / 5 | Affordable unmanned platforms, propulsion and space systems may win larger programs. Thesis, risks & sourcesWhat must go rightMove development projects into funded repeat production. What would break the thesisPrograms may not scale; procurement timing, development spending and dilution. Before assessing cheapnessDistinguish prototypes and contract ceilings from funded production and earned revenue. Exceptional-return scenario10× depends on program selection, funding and scalable margins. Company materials describe unmanned systems, propulsion, hypersonics and space capabilities. Company source ↗ Company facts → |
$41.09Stored close · 2026-10-30-68.6%From 252-session closing peak
63-session change -16.5%252-session change -55.0%
Revenue growth 30.5%Net margin 2.0%ROE 0.9%EPS acceleration -133.3 ppReporting period 2026-06-28SEC · 2026-08-04 ↗
|
| ISRGIntuitive SurgicalSurgical roboticsComparison businesses | Research priority★★★☆☆3 / 5 | RiskSubstantial3 / 5 | An installed surgical robot base can support recurring instruments and service demand. Thesis, risks & sourcesWhat must go rightGrow procedures and system utilization with healthy recurring economics. What would break the thesisHospital budgets, competition, regulatory issues and high entry expectations. Before assessing cheapnessTrack procedure growth and recurring gross profit; distinguish placements from utilization. Exceptional-return scenarioEstablished medical technology comparison, not a validated 10× candidate. Company investor materials describe robotic-assisted surgery systems and recurring products. Company source ↗ Company facts → |
$436.87Stored close · 2026-11-02-26.3%From 252-session closing peak
63-session change +18.6%252-session change -17.6%
Revenue growth 21.7%Net margin 25.5%ROE 18.5%EPS acceleration -50.1 ppReporting period 2026-09-30SEC · 2026-10-21 ↗
|
| NTRANateraMolecular diagnosticsCommercial growth | Research priority★★★☆☆3 / 5 | RiskHigh4 / 5 | Clinical adoption of molecular testing may expand monitoring and diagnostic demand. Thesis, risks & sourcesWhat must go rightGrow reimbursed tests with improving cash collections and unit economics. What would break the thesisReimbursement, clinical evidence, litigation and funding requirements. Before assessing cheapnessCompare recognized revenue with collections, test mix and cash burn. Exceptional-return scenario10× requires clinical adoption and durable reimbursement economics. Investor materials describe cell-free DNA testing across clinical applications. Company source ↗ Company facts → |
$414.30Stored close · 2026-10-30-5.0%From 252-session closing peak
63-session change +53.2%252-session change +114.9%
Revenue growth 37.7%Net margin -7.1%ROE -10.6%EPS acceleration —Reporting period 2026-06-30SEC · 2026-08-07 ↗
|
| GHGuardant HealthOncology diagnosticsCommercial growth | Research priority★★★☆☆3 / 5 | RiskExtreme5 / 5 | Blood-based oncology testing and screening may broaden the addressable patient population. Thesis, risks & sourcesWhat must go rightGrow reimbursed testing and reduce cash consumption as volumes scale. What would break the thesisReimbursement, screening adoption, competition and continued losses. Before assessing cheapnessInspect test-level economics, collections and funded runway; revenue growth alone is insufficient. Exceptional-return scenario10× needs profitable adoption at scale; clinical usefulness is not proof of shareholder returns. July 30, 2026 release: Q2 revenue of $335.0m, up 44%, with continuing losses. Company source ↗ Company facts → |
$178.80Stored close · 2026-10-30-4.5%From 252-session closing peak
63-session change +12.6%252-session change +147.4%
Revenue growth 44.3%Net margin -38.3%ROE —EPS acceleration —Reporting period 2026-06-30SEC · 2026-07-30 ↗
|
| TMDXTransMedicsOrgan transplant technologyCommercial growth | Research priority★★★☆☆3 / 5 | RiskHigh4 / 5 | Organ preservation and transplant logistics may increase the use of available donor organs. Thesis, risks & sourcesWhat must go rightExpand transplant volumes and logistics efficiency with sustainable margins. What would break the thesisClinical or regulatory setbacks, logistics costs and hospital adoption. Before assessing cheapnessSeparate technology and logistics economics; include aircraft and other capital needs. Exceptional-return scenario10× needs repeatable clinical adoption and profitable capital-efficient expansion. Company investor materials describe the Organ Care System and transplant logistics. Company source ↗ Company facts → |
$65.99Stored close · 2026-10-30-56.1%From 252-session closing peak
63-session change -19.1%252-session change -50.9%
Revenue growth 20.7%Net margin 22.7%ROE 29.3%EPS acceleration 16.0 ppReporting period 2026-06-30SEC · 2026-08-04 ↗
|
| NETCloudflareCloud network & securityCommercial growth | Research priority★★★☆☆3 / 5 | RiskHigh4 / 5 | Security and developer services can grow on a shared global network. Thesis, risks & sourcesWhat must go rightExpand paid enterprise adoption while improving GAAP profitability. What would break the thesisCompetition, service failures, network spending and share-based compensation. Before assessing cheapnessReconcile adjusted profit with GAAP losses, cash flow and diluted shares. Exceptional-return scenario10× requires sustained adoption plus entry-multiple discipline. August 6, 2026 release reports revenue growth alongside a GAAP operating loss. Company source ↗ Company facts → |
$280.70Stored close · 2026-10-30-22.2%From 252-session closing peak
63-session change -0.7%252-session change +23.4%
Revenue growth 35.9%Net margin -8.2%ROE -12.7%EPS acceleration —Reporting period 2026-06-30SEC · 2026-08-06 ↗
|
| CRWDCrowdStrikeCybersecurityComparison businesses | Research priority★★★☆☆3 / 5 | RiskHigh4 / 5 | Security platform consolidation may increase recurring customer spending. Thesis, risks & sourcesWhat must go rightSustain retention, cross-selling and reliable service delivery. What would break the thesisService incidents, liability, competition and elevated valuation. Before assessing cheapnessTrack recurring revenue, renewal concessions and free cash flow after dilution. Exceptional-return scenarioEstablished software comparison; no supported 10×/100× thesis. Company investor materials describe the Falcon cybersecurity platform. Company source ↗ Company facts → |
$241.81Stored close · 2026-11-02-13.3%From 252-session closing peak
63-session change +14.5%252-session change +79.6%
|
| DDOGDatadogCloud observabilityCommercial growth | Research priority★★★☆☆3 / 5 | RiskHigh4 / 5 | More complex cloud and AI workloads require monitoring and security tools. Thesis, risks & sourcesWhat must go rightExpand paid usage while maintaining retention and cash efficiency. What would break the thesisCloud-spend optimization, competition and share-based compensation. Before assessing cheapnessInspect consumption trends, customer concentration and per-share cash economics. Exceptional-return scenario10× depends on exceptional sustained growth and a reasonable entry price. Company publishes Q2 2026 results and materials on observability and security. Company source ↗ Company facts → |
$235.27Stored close · 2026-10-30-19.8%From 252-session closing peak
63-session change -14.0%252-session change +50.8%
Revenue growth 35.6%Net margin 4.5%ROE 4.1%EPS acceleration 985.7 ppReporting period 2026-06-30SEC · 2026-08-06 ↗
|
| DUOLDuolingoDigital educationCommercial growth | Research priority★★★☆☆3 / 5 | RiskHigh4 / 5 | A broad learning audience can support paid subscriptions and additional courses. Thesis, risks & sourcesWhat must go rightConvert engagement into retained paid users without excessive acquisition costs. What would break the thesisAI competition, weaker monetization, churn and platform dependence. Before assessing cheapnessCompare bookings, recognized revenue, paid retention and free cash flow. Exceptional-return scenario10× needs durable monetization, not just growth in free users. Company investor materials describe its learning platform and subscription business. Company source ↗ Company facts → |
$131.59Stored close · 2026-10-30-51.4%From 252-session closing peak
63-session change -3.1%252-session change -51.8%
Revenue growth 18.3%Net margin 35.9%ROE 29.1%EPS acceleration -51.1 ppReporting period 2026-06-30SEC · 2026-08-06 ↗
|
| APPAppLovinAdvertising softwareCommercial growth | Research priority★★★☆☆3 / 5 | RiskExtreme5 / 5 | Better ad targeting and measurement can attract advertiser spending. Thesis, risks & sourcesWhat must go rightDemonstrate repeat advertiser returns and diversify demand profitably. What would break the thesisPlatform policy, privacy rules, advertiser concentration and valuation. Before assessing cheapnessCheck organic sales, cash quality, leverage and dependence on external platforms. Exceptional-return scenario10× is an exceptional outcome; recent operating growth is not a return forecast. Company investor materials describe advertising software and its performance platform. Company source ↗ Company facts → |
$228.85Stored close · 2026-11-02-68.8%From 252-session closing peak
63-session change -45.5%252-session change -63.1%
Revenue growth 52.8%Net margin 64.6%ROE 139.4%EPS acceleration -55.9 ppReporting period 2026-06-30SEC · 2026-08-05 ↗
|
| QBTSD-Wave QuantumQuantum computingFrontier technology | Research priority★★☆☆☆2 / 5 | RiskExtreme5 / 5 | Quantum optimization and computing could find repeat commercial uses. Thesis, risks & sourcesWhat must go rightTurn pilot activity into repeat orders and revenue that covers growing costs. What would break the thesisLumpy system sales, limited commercial demand, cash burn and competing approaches. Before assessing cheapnessValue recognized recurring demand separately from bookings and one-off system sales. Exceptional-return scenario10× remains a speculative adoption scenario; a technology headline is not proof. Q2 2026 financial results disclose operating investment and losses. Company source ↗ Company facts → |
$10.65Stored close · 2026-10-30-71.3%From 252-session closing peak
63-session change -46.7%252-session change -68.9%
Revenue growth -0.6%Net margin -2001.6%ROE -23.0%EPS acceleration —Reporting period 2026-06-30SEC · 2026-08-06 ↗
|
| RGTIRigetti ComputingQuantum computingFrontier technology | Research priority★★☆☆☆2 / 5 | RiskExtreme5 / 5 | Superconducting quantum processors may benefit if scalable useful systems emerge. Thesis, risks & sourcesWhat must go rightDemonstrate reliable systems and convert technical milestones into paying demand. What would break the thesisHardware roadmap misses, competing architectures, cash burn and dilution. Before assessing cheapnessCheck system revenue, cash runway and financing needs before revenue multiples. Exceptional-return scenario10× is a tail outcome with technical and commercial failure risk. Investor overview describes the full-stack superconducting platform and Q2 2026 reporting. Company source ↗ Company facts → |
$11.25Stored close · 2026-10-30-74.6%From 252-session closing peak
63-session change -29.8%252-session change -71.5%
Revenue growth —Net margin —ROE -44.4%EPS acceleration —Reporting period 2026-06-30SEC · 2026-08-06 ↗
|
| RXRXRecursionDrug discoveryFrontier technology | Research priority★★☆☆☆2 / 5 | RiskExtreme5 / 5 | Computational discovery may produce valuable medicines and partnerships. Thesis, risks & sourcesWhat must go rightPositive clinical evidence and meaningful partner milestones. What would break the thesisTrial failure, regulatory setbacks, cash burn and dilution. Before assessing cheapnessUse risk-adjusted clinical programs and cash runway, not a software revenue multiple. Exceptional-return scenarioBinary clinical outcomes make 10× scenarios highly uncertain; capital loss is possible. Company describes a clinical-stage pipeline and AI-enabled drug discovery platform. Company source ↗ Company facts → |
$4.03Stored close · 2026-10-30-28.7%From 252-session closing peak
63-session change +26.7%252-session change -31.3%
Revenue growth -60.1%Net margin -945.9%ROE -56.7%EPS acceleration —Reporting period 2026-06-30SEC · 2026-08-05 ↗
|
| ENVXEnovixBattery technologyFrontier technology | Research priority★★☆☆☆2 / 5 | RiskExtreme5 / 5 | Higher energy-density batteries may win demanding device applications. Thesis, risks & sourcesWhat must go rightCustomer qualification, manufacturing yield and profitable volume production. What would break the thesisProduction yield, delayed qualification, cash burn and funding needs. Before assessing cheapnessModel yield, unit cost and funded capacity before extrapolating design wins. Exceptional-return scenario10× requires successful industrial scaling; prototype performance is insufficient. Company investor overview; manufacturing and qualification remain key diligence topics. Company source ↗ Company facts → |
$3.15Stored close · 2026-10-30-74.2%From 252-session closing peak
63-session change -25.4%252-session change -73.2%
Revenue growth 20.8%Net margin -473.9%ROE -81.0%EPS acceleration —Reporting period 2026-07-05SEC · 2026-08-12 ↗
|
| LEUCentrus EnergyNuclear fuelFrontier technology | Research priority★★☆☆☆2 / 5 | RiskExtreme5 / 5 | Domestic enrichment and advanced-reactor fuel may become important supply constraints. Thesis, risks & sourcesWhat must go rightSecure funded demand and scale enrichment capacity at viable unit costs. What would break the thesisPolicy dependence, supply restrictions, construction funding and timing of reactor demand. Before assessing cheapnessSeparate existing fuel supply economics from still-to-be-funded enrichment expansion. Exceptional-return scenarioA speculative scaling scenario; funding and dilution can overwhelm operating progress. Company materials describe nuclear fuel supply, enrichment technology and HALEU capabilities. Company source ↗ Company facts → |
$103.29Stored close · 2026-10-30-73.1%From 252-session closing peak
63-session change -44.1%252-session change -73.6%
Revenue growth 14.0%Net margin 10.2%ROE 5.7%EPS acceleration 20.3 ppReporting period 2026-06-30SEC · 2026-08-06 ↗
|
| QUBTQuantum Computing Inc.Quantum & photonicsFrontier technology | Research priority★☆☆☆☆1 / 5 | RiskExtreme5 / 5 | Photonic products and foundry services may develop commercial demand. Thesis, risks & sourcesWhat must go rightVerify repeat external orders, recognized revenue and production economics. What would break the thesisUnproven commercial scale, execution, cash consumption and dilution. Before assessing cheapnessRequire customer and revenue evidence before applying a sales multiple. Exceptional-return scenarioNo support for a 100× investment thesis; commercial evidence must come first. Company investor relations; valuation and sustained commercial scale require further diligence. Company source ↗ Company facts → |
$6.60Stored close · 2026-10-30-60.5%From 252-session closing peak
63-session change -24.5%252-session change -57.5%
Revenue growth 9000.0%Net margin -152.5%ROE -0.9%EPS acceleration —Reporting period 2026-06-30SEC · 2026-08-10 ↗
|
No companies match these filters. Widen a threshold or remove a condition.
SCENARIO LAB
Start with a dated market cap from a trusted source. These are your assumptions, not live company data. See how dilution and the future valuation multiple change the sales required for a share-price return.
Enter positive market cap, annual revenue and price-to-sales; share growth must be 0–1000%. Missing or invalid inputs produce no estimate.
Illustrative scenarios from your inputs — not price targets
Future equity market cap = current cap × share-price multiple × (1 + new shares / current shares). Required annual sales = future equity cap / assumed equity price-to-sales. Revenue CAGR = (required sales / current annual sales)^(1 / years) − 1. The model excludes dividends, taxes and currency effects. It does not price bankruptcy risk or establish that a future sales multiple is reasonable. Clinical-stage biotechnology and banks need different valuation models.
Stars rank the order of further research for this particular 2–3 year brief. They are editorial assessments, not model scores, return forecasts or buy recommendations. The same rating is a tie; row order within it is not a finer ranking.
★★★★★ requires a verified attractive entry valuation and a complete thesis review; no company receives it here. ★★★★☆ prioritizes a visible commercial catalyst. ★★★☆☆ means material questions remain. ★★☆☆☆ needs technical, clinical or commercial milestones. ★☆☆☆☆ needs stronger revenue evidence before a return thesis. Reviews expire after 90 days.
Risk describes business and financing uncertainty on an editorial 1–5 scale. 3 is substantial, 4 high and 5 extreme. It is not a loss probability, and all rows carry valuation risk.
SEC facts and daily price history reuse the existing FinEdg data store. SEC snapshot as of 2026-11-04; page observed 2026-11-04 17:24 UTC. A covered issuer can still have missing metrics.
Revenue growth compares the latest supported quarter with a year earlier. Net margin uses four matched quarters. A missing value stays unavailable. A stored close must be no more than seven calendar days old; it is not a live quote. Price changes compare closes 63 or 252 stored sessions apart; they require 64 or 253 valid observations, respectively. They exclude dividends and are historical, not return forecasts. ROE uses trailing-four-quarter net income over current reported equity; EPS acceleration is the change in year-on-year EPS growth, in percentage points. Sorting is descending with missing observations last, and does not rank cheapness. The drawdown compares that close with the maximum of the last 252 stored daily closes, not total return or intrinsic value.
Price provenance: Daily EOD closes from the BibaMoney price store (splits reflected, cash dividends not).
Algoseek API access has been checked separately. Its feed is not the source of this public table; display rights and integration remain unconfirmed. No Algoseek observations are exposed here.
Not verified in this view. A 13F reports quarterly holdings, not a real-time trade tape. Purchases require comparison of share counts across matched filings, with amendments and corporate actions handled. Short positions are omitted. The Q2 2026 reporting deadline was August 14, 2026. SEC Form 13F guidance ↗
These 44 names are a curated research list, not a screen proving capitalization below $10bn. A lower stock price, a drawdown, or a smaller capitalization than a competitor does not establish a bargain.